Mitochondria generate the majority of cellular ROS as a byproduct of oxidative phosphorylation, and mitochondrial GSH is the primary defense against this constant oxidative burden
Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus
GLP1RAs can be effective for the treatment of obstructive sleep apnea, a condition associated with elevated white matter hyperintensity burden, microstructural damage, and cognitive impairment [37]
This helps the body burn fat more efficiently and increases energy balance throughout the day
GLP-1 receptor agonists are commonly associated with gastrointestinal adverse events, which may lead to dehydration in some people [112]
Underwriting and claims considerations Underwriting The increasing use of incretin-based therapies promises to significantly influence underwriting risk assessment, illustrating the need for underwriting practices to evolve alongside medical innovation